Last reviewed · How we verify

NCT03560310: TACSI

Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome

Active, enrolled Phase 4 Last updated 2 September 2025
What this trial tests

Phase 4 trial testing Ticagrelor 90mg twice daily and ASA 75-100 mg daily in Acute Coronary Syndrome in 2,201 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
29 June 2018
Primary endpoint
13 March 2025
15 February 2035

Quick facts

Lead sponsorVastra Gotaland Region
PhasePhase 4
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment2,201
Start date29 June 2018
Primary completion13 March 2025
Estimated completion15 February 2035
Sites22 locations across Denmark, Finland, Sweden, Norway, Iceland

Drugs / interventions tested

Conditions studied

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CABG in patients with acute coronary syndrome.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
    Galli M, Angiolillo DJ. · · 2022 · cited 27× · PMID 36093167 · DOI 10.3389/fcvm.2022.975969
  2. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
    Jeppsson A, James S, Moller CH, Malm CJ, et al · · 2025 · cited 11× · PMID 40888737 · DOI 10.1056/nejmoa2508026
  3. Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial.
    Malm CJ, Alfredsson J, Erlinge D, Gudbjartsson T, et al · · 2023 · cited 8× · PMID 36681173 · DOI 10.1016/j.ahj.2023.01.011
  4. Antithrombotic strategies for preventing graft failure in coronary artery bypass graft.
    Mauro MS, Finocchiaro S, Calderone D, Rochira C, et al · · 2024 · cited 6× · PMID 38491265 · DOI 10.1007/s11239-023-02940-5
  5. Antiplatelet therapy around CABG: the latest evidence.
    Sandner S, Redfors B, Gaudino M. · · 2023 · cited 5× · PMID 37751394 · DOI 10.1097/hco.0000000000001078
  6. Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real-World Data Utilization.
    Su L, Chen L, Betigeri S, Dreyer N, et al · · 2025 · cited 3× · PMID 40827586 · DOI 10.1002/cpt.70033
  7. Short- and long-term outcomes of ST-segment elevation myocardial infarction treated with CABG: a population-based cohort study.
    Saura E, Anttila V, Gunn J, Kytö V. · · 2025 · PMID 40374230 · DOI 10.1136/bmjopen-2024-089451

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

Other Vastra Gotaland Region trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03560310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing